Nuclear medicine imaging for bone metastases assessment: what else besides bone scintigraphy in the era of personalized medicine?

Fiche publication

Date publication

janvier 2024

Journal

Frontiers in medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr IMPERIALE Alessio , Dr POROT Clémence , Dr SOMME François

Tous les auteurs :
Ouvrard E, Kaseb A, Poterszman N, Porot C, Somme F, Imperiale A

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/38288299

Résumé

Accurate detection and reliable assessment of therapeutic responses in bone metastases are imperative for guiding treatment decisions, preserving quality of life, and ultimately enhancing overall survival. Nuclear imaging has historically played a pivotal role in this realm, offering a diverse range of radiotracers and imaging modalities. While the conventional bone scan using Tc marked bisphosphonates has remained widely utilized, its diagnostic performance is hindered by certain limitations. Positron emission tomography, particularly when coupled with computed tomography, provides improved spatial resolution and diagnostic performance with various pathology-specific radiotracers. This review aims to evaluate the performance of different nuclear imaging modalities in clinical practice for detecting and monitoring the therapeutic responses in bone metastases of diverse origins, addressing their limitations and implications for image interpretation.